Sage Journals: Discover world-class research

Abstract

Introduction/Objectives:

Sleep disorders affect around 50 to 70 million Americans, with chronic insomnia being the most common, especially in the elderly population. With an 11-fold increase in the US office visits due to insomnia, from 0.8 to 9.4 million, between 1993 and 2015, it is imperative to identify the modifiable risk factors. The aim of our study was to examine the association of risk factors and comorbid medical conditions with insomnia in patients 65 years, and older.

Methods:

We performed a retrospective electronic medical record review of the patients aged 65 years and older, who visited our suburban internal medicine office between July 1, 2020 and June 30, 2021. Patients were divided into insomnia group, and the group without insomnia. The associated variables were compared.

Results:

Among 2431 patients, 247 patients (10.2%) had insomnia. Mean ages of the patients in the insomnia group and the group without insomnia were comparable (77 ± 8.1 year vs 76 ± 7.5 year; P = .211). There was a significantly greater frequency of women in the insomnia group compared to the group without insomnia (63.2% vs 55.5%; P = .022). In the insomnia group, there were significantly higher frequencies of association of certain comorbidities compared to the group without insomnia, such as dementia (6.5% vs 3.4%; P = .015), depression (30.8% vs 14.9%; P < 0.001), anxiety disorder (34.4% vs 17.4%; P < .001), atrial fibrillation (19.4% vs 13.4%; P = .01), and chronic pain disorders (32.8% vs 18.9%; P < .001). Logistic regression analysis showed significantly greater odds of insomnia in patients who had depression (OR = 1.860, 95% CI 1.342–2.576; P < .001), anxiety (OR = 1.845, 95% CI 1.342-2.537; P < .001), and chronic pain disorders (OR = 1.901, 95% CI 1.417-2.549; P < .001).

Conclusions:

Female sex, dementia, depression, anxiety, chronic pain disorders, and atrial fibrillation are associated with insomnia in the elderly patients. Presence of depression, anxiety, and chronic pain disorders are associated with greater odds of having insomnia in the elderly patients.

Keywords

insomnia elderly population risk factors of insomnia insomnia in elderly sleep disorder

Introduction

Sleep disorders affect around 50 to 70 million Americans, with insomnia being the most common.¹ Insomnia can be divided into short term and chronic. The International Classification for Sleep Disorders, Version 3 (ICSD-3) states that in order to be diagnosed with chronic insomnia, one needs to have one of the following issues for a minimum of 3 days a week for at least 3 months: difficulty initiating sleep, difficulty maintaining sleep, waking earlier than desired, resistance to going to bed on appropriate schedule, or difficulty sleeping without a parent or caregiver.² About 10% of the US population have been found to have chronic insomnia.¹ Short term insomnia follows the same criteria as chronic insomnia but for less than 3 months.³

Insomnia has an involved pathophysiology consisting of psychological cognitive arousal, altered circadian rhythm, decreased function of the sleep-wake switch, and homeostatic mechanisms.⁴ In patients who are 65 years and older, these factors play a role more commonly than the younger population. For example, it has been illustrated that sleep efficiency decreases after the age of 60 as this population spends less time in REM and slow wave sleep.⁵

Chronic insomnia has been linked to many other disorders, whether it be medical, neurological, or mental. There are several non-modifiable factors that have been shown to contribute to insomnia such as genetics and personality traits.⁴ Additionally, there has been an association of insomnia identified in several groups, such as military personnel and veterans, those with traumatic brain injury (TBI), depression, anxiety, substance abuse, and cardiovascular disorders.^3,4 The increase in the diagnosis of insomnia has led to an 11-fold increase, from 0.8 million to 9.4 million, in the US outpatient office visits from 1993 to 2015. This has led to the risk factors being investigated that have a relationship with the diagnosis of insomnia.⁵ Additionally, insomnia is common in the older population with about 30% to 48% having insomnia symptoms when compared to the 12% to 20% incidence in the general population.⁵

Guidelines to manage chronic insomnia recommend starting with Cognitive Behavioral Therapy for Insomnia (CBTI).^4,5 Subsequent options are usually pharmacologic, where one can use many drugs such as suvorexant, eszopiclone, and zaleplon.⁶ However, when graded on outcome and appropriateness of use in the strategy for best patient care, all pharmacologic agents were given the grade of being “weak.”⁷ In the attempt to manage insomnia one can prioritize treating comorbid medical conditions that may exhibit a bidirectional relationship with insomnia.⁵

There is a lack of agreement among various risk factors and comorbid medical conditions and their associations with insomnia.^2,8Managing these risk factors appropriately may lead to better management of insomnia as well as the underlying medical conditions. In this study, our aim was to study the association of risk factors and comorbid medical conditions that were associated with insomnia in the elderly population.

Materials and Methods

Study Design and Setting

Our study was a retrospective non-matched case-control study of the entire population of our patients who were 65 years of age, or older, who visited our suburban internal medicine office between July 1, 2020 and June 30, 2021, which involved a convenience sampling of the existing electronic medical records.

Participants

Patients aged 65 years or older who visited our internal medicine office between July 1, 2020 and June 30, 2021 were included. We excluded patients who were younger than 65 years of age; and patients 65 years of age or older who visited our internal medicine office before July 1, 2020 and after June 30, 2021.

Variables

We collected the following data on each patient: age, sex, race, alcohol use, tobacco use, recreational drug use; comorbid medical conditions, such as hypertension, diabetes mellitus (DM), cerebrovascular accident, seizure disorder, traumatic brain injury, dementia, Parkinson’s disease, depression, bipolar disorder, anxiety disorder, schizophrenia, coronary artery disease (CAD), congestive heart failure (CHF), atrial fibrillation, other cardiac arrhythmia, chronic obstructive pulmonary disease (COPD), asthma, obstructive sleep apnea (OSA), gastroesophageal reflux disorder (GERD), liver cirrhosis, chronic kidney disease (CKD), anemia, cancer, hypothyroidism, hyperthyroidism, osteoarthritis, other rheumatologic diseases, peripheral neuropathy, chronic pain disorders, frail (assessed by Katz Index of risk assessment of activities of daily living, in which a score of 6 was interpreted as independent or not-frail, while a score of 0-5 was interpreted as non-independent or frail), and insomnia. We also collected the data of systolic and diastolic blood pressures, body mass index (BMI), total cholesterol, low density lipoprotein cholesterol (LDL-C), high density lipoprotein cholesterol (HDL-C), and triglyceride level, vitamin B12, vitamin D, estimated glomerular filtration rate (eGFR), hemoglobin, thyroid stimulating hormone (TSH), folate level, aspartate aminotransferase (AST), alanine aminotransferase (AST), mortality; use of medications, such as antihypertensive medication, oral hypoglycemic agent (OHA), statin, antidepressants, benzodiazepines, non-benzodiazepines sleeping medication, anticoagulants, anti-epileptic medications, long-acting beta-agonist (LABA), short-acting beta-agonist (SABA), proton pump inhibitor (PPI), central nervous system stimulants, and histamine receptor antagonist. We recorded the collected data into a Microsoft Excel (2016, Redmond, Washington, USA) spreadsheet.

Data Source and Access

This study was reviewed and approved by the Institutional Review Board of the Cooper University Healthcare (CUHC). Permission was granted to use materials that were collected solely for research study purposes as per the) requirements, and the informed consent waivers were granted by the Institutional Review Board. This study was fully compliant with the ethical standards set forth by the CUHC. All investigators had full access to the data available only in the electronic medical records of the list of patients approved by the medical informatics of the CUHC, who were selected based on the selection criteria of the study.

Bias

To address the potential for unmeasured confounding associated with insomnia, we excluded patients who had known comorbidity that could have been associated with insomnia, such as shift work insomnia, narcolepsy, terminally ill patients under hospice care, patients with periodic limb movement disorder, frequent international travelers experiencing jet lag, and patients with metabolic encephalopathy.

Study Size

The entire population of our 2431 patients who were 65 years of age, or older, who visited our internal medicine office between July 1, 2020 and June 30, 2021.

Statistical Methods

Statistical analysis was computed by using SPSS (Statistical Package for the Social Sciences, version 15.01, IBM, Armonk, New York, USA) software. The patients were divided into 2 groups: first group represented the patients who suffered from insomnia, and the second group consisted of patients who did not have insomnia. For the continuous variables, data distribution was tested by using a test of skewness. Those with a value between 1 and −1 were normally distributed and an independent t-test was used for analysis. Those with skewness that were greater than 1 or less than −1 illustrated that the data was non-parametric and Mann-Whitney U-test was used for the analysis. Categorical variables were analyzed using either chi-square tests or Fisher exact tests. A decision was made between which one based on the expected value of the data. Logistic regression was used to model the outcome of insomnia. Independent variables within the model were determined by using the gradient boosting model through a function that determines the most important data elements that predict insomnia. In this study, significance was defined as a P < .05.

Results

A total of 2431 patients were included in this study. Two hundred forty seven (10.2%) patients had insomnia and 2184 (89.8%) did not have insomnia (Table 1). There was no statistically significant difference in the mean ages between the patients in the insomnia group and the group without insomnia (77 ± 8.1 year vs 76 ± 7.5 year; P = .211; Table 1). There was significantly greater frequency of women in the insomnia group compared to the group without insomnia (63.2% vs 55.5%; P = .022; Table 1). The majority of patients in the insomnia group and in the group without insomnia were of White race (79.4% vs 77.2%), followed by of Black (16.1% vs 18.8%) and other races (4.5% vs 4.0%). There was no significant difference in the race distribution between the 2 groups. Analysis of social factors, such as tobacco use, alcohol use, and recreational drug use, did not show significant differences between the patients with insomnia and patients without insomnia (Table 1). Similarly, there was no statically significant difference in the systolic and diastolic blood pressures, BMI, blood levels of total cholesterol, LDL-C, HDL-C, triglyceride, vitamin B12, vitamin D, hemoglobin, TSH, folate, AST, AST, and eGFR between the 2 groups (Table 1).

Table 1.

Baseline Characteristics and Laboratory Parameters.

Variable	Variable	Patients with insomnia (n = 247)	Patients without insomnia (n = 2184)	P
Age	Years, mean (SD)	77.3 (8.1)	76.7 (7.5)	.211
Sex	Male, n (%)	91(36.8)	971 (44.5)	.022
Sex	Female, n (%)	156 (63.2)	1213 (55.5)	.022
Race	White, n (%)	196 (79.4)	1686 (77.2)	.449
	Black, n (%)	40 (16.1)	411 (18.8)
	Other, n (%)	11 (4.5)	87 (4.0)
Social	Tobacco use, n (%)	100 (40.5)	960 (44.0)	.297
	Alcohol use, n (%)	130 (52.6)	1132 (51.8)	.811
	Recreational drug use, n (%)	7 (2.8)	53 (2.4)	.698
Vitals	Systolic BP (mmHg), mean (SD)	126 (17)	129 (36)	.453
Vitals	Diastolic BP (mmHg), mean (SD)	74 (9)	74 (10)	.764
Weight	BMI (kg/m²), mean (SD)	27.5 (5.5)	28.1 (6.0)	.201
Lab values	Total Cholesterol (mg/dL), mean (SD)	172.2 (43.5)	169.6 (59.1)	.500
	LDL (mg/dL), mean (SD)	94.9 (34.5)	91.9 (35.1)	.209
	HDL (mg/dL), mean (SD)	55.8 (15.9)	56.8 (41.5)	.704
	TG (mg/dL), mean (SD)	102.7 (54.1)	112.0 (64.2)	.006
	Vit B₁₂ (pg/mL), mean (SD)	753.1 (536.3)	765.9 (601.7)	.792
	Vit D (ng/mL), mean (SD)	37.7 (13.2)	39.4 (17.5)	.204
	eGFR (mL/min/1.73 m²), mean (SD)	61.6 (15.8)	62.1 (16.9)	.699
	Hb (g/dL), mean (SD)	12.9 (1.9)	12.9 (2.7)	.938
	TSH (mIU/L) (median, 25th-75th)	2.00 (1.20-3.08)	2.01 (1.31-3.00)	.639
	Folate (ng/mL) (median, 25th-75th)	16.8 (12.5-20.0)	17.0 (11.7-20.0)	.807
	ALT (U/L) (median, 25th-75th)	17 (13-22)	17 (13-23)	.389
	AST (U/L) (median, 25th-75th)	20 (17-25)	21 (17-25)	.764

Abbreviations: n, number of patients; SD, standard deviation; BP, blood pressure; BMI, body mass index; LDL, low-density lipoprotein; HDL, high-density lipoprotein; TG, triglycerides; Vit B₁₂, Vitamin B₁₂; Vit D, Vitamin D; eGFR, estimated glomerular filtration rate; Hb, Hemoglobin; TSH, thyroid stimulating hormone; ALT, alanine transaminase; AST, aspartate aminotransferase.

We found significantly higher frequencies of association of several co-morbid medical conditions in the group of patients with insomnia compared to the group of patients without insomnia, such as dementia (6.5% vs 3.4%; P = .015), depression (30.8% vs 14.9%; P < .001), anxiety disorder (34.4% vs 17.4%; P < .001), atrial fibrillation (19.4% vs 13.4%; P = .01), and chronic pain disorders (32.8% vs 18.9%; P < .001; Figure 1). There were no statistically significant differences between the 2 groups in the frequencies of the comorbidities, such as hypertension, diabetes mellitus, cerebrovascular accident, seizure disorder, traumatic brain injury, Parkinson’s disease, bipolar disorder, schizophrenia, coronary artery disease, congestive heart failure, other cardiac arrhythmias excluding atrial fibrillation, chronic obstructive pulmonary disease, asthma, obstructive sleep apnea, gastroesophageal reflux disease, liver cirrhosis, chronic kidney disease, anemia, cancer, hypothyroidism, hyperthyroidism, osteoarthritis, other rheumatological diseases, peripheral neuropathy, and frailty; and mortality (Table 2).

Figure 1.

Frequencies of associated medical diagnoses.

Table 2.

Comparative Association of Comorbid Medical Conditions and Mortality.

Variable	Variable	Patients with insomnia (n = 247)	Patients without insomnia (n = 2184)	P
Comorbidities	Hypertension, n (%)	212 (85.9)	1797 (82.3)	.619
	DM, n (%)	66 (26.7)	623 (28.5)	.551
	CVA, n (%)	88 (4.4)	137 (6.3)	.388
	Seizure, n (%)	4 (1.6)	33 (1.5)	.786
	TBI, n (%)	1 (0.4)	11 (0.5)	1.000
	Dementia, n (%)	16 (6.5)	74 (3.4)	.015
	Parkinson’s Ds, n (%)	2 (0.8)	19 (0.9)	1.000
	Depression, n (%)	76 (30.8)	326 (14.9)	<.001
	Bipolar Ds, n (%)	3 (1.2)	21 (1.0)	.729
	Anxiety Dis, n (%)	85 (34.4)	380 (17.4)	<.001
	Schizophrenia, n (%)	0 (0.0)	7 (0.3)	1.000
	CAD, n (%)	54 (21.9)	448 (20.5)	.619
	CHF, n (%)	18 (7.3)	134 (6.1)	.478
	Atrial fibrillation, n (%)	48 (19.4)	293 (13.4)	.010
	Other cardiac arrhythmias, n (%)	34 (13.8)	279 (12.8)	.660
	COPD, n (%)	19 (7.7)	142 (6.5)	.499
	Asthma, n (%)	35 (14.2)	237 (10.9)	.117
	OSA, n (%)	38 (15.4)	269 (12.3)	.169
	GERD, n (%)	88 (35.6)	675 (30.9)	.130
	Cirrhosis, n (%)	3 (1.2)	22 (1.0)	.736
	CKD, n (%)	40 (16.2)	287 (13.1)	.183
	Anemia, n (%)	44 (17.8)	306 (14.0)	.107
	Cancer, n (%)	84 (34.0)	623 (28.5)	.072
	Hypothyroidism, n (%)	47 (19.0)	386 (17.7)	.600
	Hyperthyroidism, n (%)	2 (0.8)	21 (1.0)	1.000
	Osteoarthritis, n (%)	89 (36.0)	659 (30.2)	.059
	Other Rheum Ds, n (%)	41 (16.6)	458 (21.0)	.107
	Peripheral neuropathy, n (%)	21 (8.5)	153 (7.0)	.388
	Chronic pain dis, n (%)	81 (32.8)	412 (18.9)	<.001
	Frail, n (%)	13 (5.1)	118 (5.4)	.694
Mortality	Dead, n (%)	16 (6.5)	95 (4.3)	.129

Abbreviations: n, number of patients; DM, diabetes mellitus; CVA, cerebrovascular accident; TBI, traumatic brain injury; Parkinson’s Ds, Parkinson’s disease; Bipolar Ds, bipolar disorder; Anxiety Dis, Anxiety disorder; CAD, coronary artery disease; CHF, congestive heart failure; COPD, chronic obstructive pulmonary disease; OSA, obstructive sleep apnea; GERD, gastroesophageal reflux disorder; CKD, chronic kidney disease; Other Rheum Ds, other rheumatological disorders; Chronic pain dis, chronic pain disorder.

Analysis of medication usage showed that the group with insomnia had a significantly higher usage of some medications compared to the group without insomnia, such as antidepressants (39.7% vs 21.4%; P < .001), benzodiazepines (24.3% vs 12.2%; P < .001), non-benzodiazepines prescription sleeping medications (21.9% vs 3.2%; P < .001), and anticoagulants (26.7% vs 20.8%; P = .033). There were no significant differences in the use of antihypertensives, oral hypoglycemics, statins, antiepileptics, long-acting beta agonists, short acting beta agonists, central nervous system stimulants, and antihistamines between the 2 groups (Table 3).

Table 3.

Comparison of Medication Use Between the Two Groups.

Medications	Patients with insomnia (n = 247)	Patients without insomnia (n = 2184)	P
Antihypertensive med, n (%)	177 (72.0)	1496 (68.6)	.281
OHA, n (%)	43 (17.4)	451 (20.7)	.229
Statin, n (%)	151 (61.1)	1374 (62.9)	.578
Antidepressants, n (%)	98 (39.7)	468 (21.4)	<.001
Benzodiazepines, n (%)	60 (24.3)	266 (12.2)	<.001
Non-benz sleep med, n (%)	54 (21.9)	69 (3.2)	<.001
Anticoagulants, n (%)	66 (26.7)	455 (20.8)	.033
Antiepileptic med, n (%)	29 (11.7)	181 (8.3)	.067
LABA, n (%)	9 (3.6)	110 (5.0)	.336
SABA, n (%)	43 (17.4)	294 (13.5)	.089
PPI, n (%)	82 (33.2)	628 (28.8)	.147
CNS stimulants, n (%)	6 (2.4)	33 (1.5)	.279
Antihistamines, n (%)	56 (22.7)	502 (23.0)	.909

Abbreviatios: n, number of patients; OHA, oral hypoglycemic agent; Non-benz sleep med, non-benzodiazepine sleeping medication; LABA, long acting beta2 agonist; SABA, short acting beta2 agent; PPI, proton pump inhibitor; CNS, central nervous system.

Logistic regression analysis showed significantly greater odds of insomnia in patients who had depression (OR = 1.860, 95% CI 1.342-2.576; P < .001), anxiety (OR = 1.845, 95% CI 1.342–2.537; P < .001), and chronic pain disorders (OR = 1.901, 95% CI 1.417–2.549; P < .001; Table 4).

Table 4.

Influence of Risk Factors and Comorbidities on Insomnia.

Variable	B	P	Exp(B)	95% CI for Exp(B)
Variable	B	P	Exp(B)	Lower	Upper
Age (years)	0.012	.178	1.013	0.994	1.031
Sex male	−0.122	.395	0.885	0.667	1.173
Race White	0.063	.712	1.065	0.761	1.491
Depression	0.620	<.001	1.860	1.342	2.576
Anxiety	0.613	<.001	1.845	1.342	2.537
Dementia	0.526	.08	1.692	0.939	3.049
Chronic pain disorders	0.642	<.001	1.901	1.417	2.549

Discussion

We found that in the elderly population, female sex, dementia, depression, anxiety, chronic pain disorder, and atrial fibrillation were associated with insomnia. A meta-analysis of sex differences in insomnia found that females were more at risk for insomnia than males, and that it was progressive with increasing age.⁹ During the peri-menopausal phase, menopausal phase, and some years after the menopause, changes in the estrogen and progesterone levels adversely influence, both the initiation and maintenance of sleep which results into insomnia.^10–12 However, after the cessation of the menopausal hormonal changes, the pathogenesis of subsequent insomnia is not well understood. In our study of elderly population, we believe that our female patients were way beyond their menopausal phase. Additionally, in the elderly population, the issues that contribute to insomnia occur in both genders, such as mood disorders, medical comorbidities, modifiable lifestyle factors, and aging.¹² Our finding of higher association of insomnia in elderly females align with the available literature.

In our study patients with dementia had a significantly increased risk for having insomnia. A systematic review and meta-analysis evaluated the risk of incident all-cause dementia in individuals with insomnia, and concluded that insomnia was associated with increased risk of all causes of dementia (RR = 1.53 95% CI 1.07–2.18, z = 2.36, P = .02).¹³ Another study investigated a longitudinal relationship between insomnia and dementia in the US adults aged 65 years or older. The subjects were followed over a 10-year period to determine if their insomnia scores at that time were associated with dementia. It was concluded that those who had increased severity in insomnia symptoms had a 45% to 58% increased risk of having dementia.¹⁴ One can argue that dementia has a bidirectional relationship with insomnia which can be illustrated by different neurobiological mechanisms. Patients with dementia of Alzheimer’s type, can have abnormal melatonin secretion patterns leading to abnormal sleep and insomnia.¹⁵ This has been confirmed in those with the clinical diagnosis of dementia of Alzheimer’s type and postmortem analysis.¹⁶ This is likely due to the dysfunctional connection between the suprachiasmatic nucleus and pineal gland which leads to a change in the circadian rhythm by disrupting normal melatonin secretion.¹⁷ The role of insomnia in dementia has been well established in patients with Parkinson’s disease. The pathogenesis involves brainstem degeneration causing dementia. The disruptions in the brainstem leads to alterations in the REM phase of sleep which causes insomnia.¹⁸ The cumulative pathogenesis of all types of dementia happens to be brain damage which leads to disruptions of the neural networks in the brain causing insomnia.¹⁹

The bidirectional association of insomnia leading to the development of dementia was demonstrated in a study that observed the effect of sleep deprivation in the brains of mice. The authors found that sleep deprivation for 3 weeks lead to accumulation of Amyloid-beta, a hallmark of Alzheimer’s dementia, in the brain extracellular space.²⁰ Additionally, looking closer to various subtypes of dementia can provide further information in the possibility of how the interaction between insomnia and dementia may occur and when insomnia presents in its course. In Alzheimer’s dementia, symptoms of insomnia tend to precede cognitive dysfunction. In patients with Parkinson’s disease, insomnia tends to happen more than 10 years later after the initial presentation.¹⁸ This could very well explain why we found no significant difference in the association of Parkinson’s disease in those with and without insomnia. In these patients, insomnia might not had manifested at the time of our data collection. It is fair to state that the relationship between dementia and insomnia is complex. Looking into what caused dementia could help prevent insomnia and offer proper management. Some types of of dementia might precede insomnia and others might happen after. Additionally, certain medication management could influence insomnia in those with certain types of dementia. For example, when treating Alzheimer’s dementia, donepezil can be associated with increased risk of insomnia.²¹ In those with insomnia receiving anticholinergic medications, it can worsen Alzheimer’s dementia. ^18,22

We found a significantly increased association of depression with insomnia. Our finding aligns with the findings of the study conducted by Bei and associates, in which they reported that symptoms of insomnia were seen in 80% to 90% of patients who had major depressive disorder.²³ In the prospective National Institute of Mental Health Epidemiologic Catchment Area study, 7954 participants were questioned about sleep complaints and psychiatric symptoms using the Diagnostic Interview Schedule, at baseline and 1 year later, and found that 14% of the participants with persistent insomnia had depression compared to less than 1% who had no sleep complaints (P < .001).²⁴ Another prospective study reported that the chronic sleep issues were associated with increased risk of developing depression.²⁵ There are several possible mechanisms how insomnia and depression could be inter-related. In individuals with depression, there happens to be an increase in the REM density, and a decrease in the time spent in short wave sleep (SWS).²⁶ Decreased SWS is also seen in patients diagnosed with insomnia. Additionally, in genetically predisposed individuals, abnormalities in the CLOCK (circadian locomotor output cycles kaput) gene results in aberrations in the suprachiasmatic nuclei pacemakers which leads to insomnia.²⁶ In patients with depression who had a genetic variant of the CLOCK gene, there was an increased risk of insomnia in their lifetime.^{26, ²⁷} An overactive hypothalamus has been noted to play a role in both insomnia and depression as well.^26,28,29 It is important to note that in many cases, the symptoms of insomnia tend to precede the diagnosis of depression, hence the knowledge of this association may play an important role in the management. For example, in the National Institute of Mental Health Epidemiologic Catchment Area study, the participants with persistent insomnia had a higher chance of developing depression (OR = 39.8; 95% CI: 19.8-80.0) compared to those whose had resolved insomnia (OR = 1.6; 95% CI: 0.5–5.3).²⁴ In another study, in participants with depression, insomnia was seen to occur before or at the same time of the making the diagnosis of depression.³⁰ Insomnia is associated with a greater severity of depression and those with insomnia also have a greater risk to relapse with depression.²³ Hence, an early identification of association of insomnia with depression may offer better management opportunities, especially in the elderly population.

In our study, patients with insomnia had a significantly greater association with anxiety. This has been observed in other studies, as well. In a community based study of 772 participants, individuals with insomnia had 17.4 times greater likelihood of having clinically significant anxiety when compared to those without insomnia.²⁹ In another epidemiologic study, insomnia had been shown to affect about 50% of those with anxiety.³¹ How anxiety and insomnia affect each other at the neurobiological level is unclear, however there are multiple proposed mechanisms. One of the mechanisms is thought to be an increased sleep reactivity.³² Increased sleep reactivity due to stress interrupts sleep by causing difficulty in falling, or staying asleep. It has been found to be linked with anxiety and insomnia.³² If the brain has neural circuits that make it prone to increased sleep reactivity, there happens to be a higher risk of insomnia and anxiety. In many cases anxiety first comes about at the same time, or after insomnia in those who have both conditions.³⁰ The knowledge of this association may help the course of management for those with insomnia. Additionally, those with anxiety tend to have a higher amount of sleep threat monitoring, whereby their anxiety overwhelms their thinking about their sleep. An example of this is focusing too much on certain aspects of their sleep such as their heart rate and other bodily functions. Cognitive behavioral therapy has been shown to help suppress these thoughts that could delay sleep and heighten arousal.³³

Our finding of significantly high association of insomnia in patients with chronic pain disorder aligns with the existing scientific literature. It is estimated that the 50% to 80% of those with chronic pain disorder have insomnia.³⁴ The potential neurobiological mechanism involving the association of insomnia and chronic pain stem from similar pathways in the brain which help us understand how these 2 conditions likely predispose each other, such as the dopaminergic and serotonergic pathways play a role in how pain is tolerated and how sleep is regulated.³⁵ A potential consequence of this association can explain how an increase in insomnia duration and severity can cause an increase in the amount of perceived pain.³⁶ One of the mechanisms happens to be an increase in the pro-inflammatory cytokines that stems from 1 having abnormal sleep, which leads to an increased pain perception and decreased pain tolerance.³⁴ A study that asked questions about insomnia, somatic complaints, and pain to volunteers concluded that those with habitual insomnia had a greater reactivity to pain. It was also seen that those who had a bad night sleep had worsened pain compared to those with a good night sleep. Also, those with more than usual pain in a certain day had worse sleep compared to those with less than usual pain.³⁷ These findings can help illustrate the bidirectional relationship between sleep and pain. Another study showed that those with chronic pain have worse sleep characterized by delayed sleep onset, increased nighttime awakening, and worse sleep quality compared to those without chronic pain.³⁸ Knowing this information about the neurobiological mechanisms and the way insomnia and chronic pain can affect each other can lead to more appropriate management of patients who present with both of these conditions. In individuals with chronic pain who have comorbid insomnia, taking steps to improve sleep has been shown to improve short and long term pain.³⁹ In others with insomnia and comorbid chronic pain, improving pain symptoms through pharmacological or non-pharmacological methods, have been shown to improve insomnia.³⁶

In our study patients with insomnia had a significantly greater association of atrial fibrillation. A population based retrospective study found that those with insomnia had a higher association of having atrial fibrillation (HR = 1.08, 95% CI 1.01–1.14).⁴⁰ Another study looked into the sleep and risk of arrhythmias, and found that those with a healthy sleep pattern had a lower risk of atrial fibrillation (HR comparing extreme categories: 0.71, 95% CI 0.64–0.80) and bradyarrhythmias (HR comparing extreme categories: 0.65, 95% CI 0.54–0.77), but not ventricular arrhythmias.⁴¹ The finding of ventricular arrhythmias not having a relation to insomnia can also help explain why in our study other cardiac arrhythmias, excluding atrial fibrillation, did not show significant association with insomnia.

We also found that use of antidepressants, benzodiazepines, non-benzodiazepines sleeping medications, and anticoagulants were significantly higher in patients with insomnia. We believe this was most likely due to underlying diagnoses for which these groups of medications were prescribed.

Our study had a few limitations. Being a retrospective chart review study, we had to rely solely on the documentation entered in the electronic medical record by the patient care teams, hence certain items, such as the exact time of onset of insomnia in relation to the onset of comorbidities, could not be reliably ascertained. The major strength of our study was having a large sample size from 1 primary care office in which the study subjects received care from a small group of primary care physicians, and were followed by their specific physicians for a long time which allowed them to chronologically document associated comorbidities and the emerging disorders over a long time period.

Conclusion

We conclude that female sex, dementia, depression, anxiety, chronic pain disorder, and atrial fibrillation are associated with insomnia in the elderly patients. Presence of depression, anxiety, and chronic pain disorders are associated with greater odds of having insomnia in the elderly patients. Further studies at different settings are needed to identify similar, or additional risk factors.

Footnotes

Acknowledgements

The authors thank Christine Rickette, RN (study coordinator) for her contribution to this study.

Author Contributions

NM and SR made substantial contributions to the study design, drafting, data acquisition and analysis, and manuscript writing. All authors contributed in data collection and manuscript writing and review. KH analyzed the data. SR contributed in revising the manuscript critically for improved intellectual content, and final approval for the version to be published.

Data Availability

The authors declare that data supporting the findings of this study are available within the article.

Declaration of Conflicting Interests

The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

Funding

The author(s) received no financial support for the research, authorship, and/or publication of this article.

Ethics

This study was reviewed and approved by the Institutional Review Board of the Cooper University Health Care (CUHC), Camden, New Jersey, USA (IRB:22-083). Permission was granted to use materials that were collected solely for research study purposes as per the Health Insurance Portability and Accountability Act (HIPPA) requirements, and the informed consent waivers were granted by the Institutional Review Board. This study was fully compliant with the ethical standards set forth by the CUHC institutional review board. All investigators had full access to the data available only in the electronic medical records of the list of patients approved by the medical informatics of the CUHC, who were selected based on the selection criteria of the study.

Informed Consent

Not applicable. Being a retrospective chart review study the Institutional Review Board waived the need for informed consent.

ORCID iDs

Roshni Gandhi

Ian Millstein

Satyajeet Roy

References

Altevogt

Colten

. (eds.). Sleep Disorders and Sleep Deprivation: An Unmet Public Health Problem. National Academies Press; 2006.

Kay-Stacey

Attarian

. Advances in the management of chronic insomnia. BMJ. 2016;354:i2123.

Riemann

Nissen

Palagini

Otte

Perlis

Spiegelhalder

. The neurobiology, investigation, and treatment of chronic insomnia. Lancet Neurol. 2015;14(5): 547–558.

Dopheide

. Insomnia overview: epidemiology, pathophysiology, diagnosis and monitoring, and nonpharmacologic therapy. Am J Manag Care. 2020;26(4 Suppl):S76–S84.

Patel

Steinberg

Patel

. Insomnia in the elderly: a review. J Clin Sleep Med. 2018;14(6):1017–1024.

Sateia

Buysse

Krystal

Neubauer

Heald

. Clinical practice guideline for the pharmacologic treatment of chronic insomnia in adults: an American academy of sleep medicine clinical practice guideline. J Clin Sleep Med. 2017;13(2):307–349.

Moloney

Ciciurkaite

Brown

. The medicalization of sleeplessness: results of U.S. office visit outcomes, 2008-2015. SSM Popul Health. 2019;8:100388.

Yamamoto

Shinzawa

Isaka

Yamakoshi

Imai

Ohashi

Hishida

; CKD-JAC Investigators. Sleep quality and sleep duration with CKD are associated with progression to ESKD. Clin J Am Soc Nephrol. 2018; 13(12):1825–1832.

Zhang

Wing

. Sex differences in insomnia: a meta-analysis. Sleep. 2006;29(1):85–93.

10.

Umeda

Kim

. Gender differences in the prevalence of chronic pain and leisure time physical activity among US adults: a NHANES study. Int J Environ Res Public Health. 2019;16(6):988.

11.

Krystal

Edinger

Wohlgemuth

Marsh

. Sleep in peri-menopausal and post-menopausal women. Sleep Med Rev. 1998;2(4):243–253.

12.

Seib

Anderson

Lee

. Prevalence and correlates of sleep disturbance in postmenopausal women: the Australian Healthy Aging of Women (HOW) Study. J Womens Health. 2014;23(2):151–158.

13.

de Almondes

Costa

Malloy-Diniz

Diniz

. Insomnia and risk of dementia in older adults: systematic review and meta-analysis. J Psychiatr Res. 2016;77:109–115.

14.

Beydoun

Weiss

Hossain

Huang

Alemu

Zonderman

. Insomnia as a predictor of diagnosed memory problems: 2006-2016 Health and Retirement Study. Sleep Med. 2021;80:158–166.

15.

Ohashi

Okamoto

Uchida

Iyo

Mori

Morita

. Daily rhythm of serum melatonin levels and effect of light exposure in patients with dementia of the Alzheimer’s type. Biol Psychiatry. 1999;45(12):1646–1652.

16.

Mishima

Tozawa

Satoh

Matsumoto

Hishikawa

Okawa

. Melatonin secretion rhythm disorders in patients with senile dementia of Alzheimer’s type with disturbed sleep-waking. Biol Psychiatry. 1999;45(4):417–421.

17.

Swaab

. Disturbance and strategies for reactivation of the circadian rhythm system in aging and Alzheimer’s disease. Sleep Med. 2007;8(6):623–636.

18.

Cipriani

Lucetti

Danti

Nuti

. Sleep disturbances and dementia. Psychogeriatrics. 2015;15(1):65–74.

19.

Deschenes

McCurry

. Current treatments for sleep disturbances in individuals with dementia. Curr Psychiatry Rep. 2009;11(1):20–26.

20.

Kang

Lim

Bateman

, et al. Amyloid-beta dynamics are regulated by orexin and the sleep-wake cycle. Science. 2009;326(5955):1005–1007.

21.

Burns

Rossor

Hecker

, et al. The effects of donepezil in Alzheimer’s disease - results from a multinational trial. Dement Geriatr Cogn Disord. 1999;10(3):237–244.

22.

Vitiello

Borson

. Sleep disturbances in patients with Alzheimer’s disease: epidemiology, pathophysiology and treatment. CNS Drugs. 2001;15(10):777–796.

23.

Bei

Asarnow

Krystal

Edinger

Buysse

Manber

. Treating insomnia in depression: Insomnia related factors predict long-term depression trajectories. J Consult Clin Psychol. 2018;86(3):282–293.

24.

Ford

Kamerow

. Epidemiologic study of sleep disturbances and psychiatric disorders. An opportunity for prevention? JAMA. 1989;262(11):1479–1484.

25.

Roberts

Shema

Kaplan

Strawbridge

. Sleep complaints and depression in an aging cohort: a prospective perspective. Am J Psychiatry. 2000;157(1):81–88.

26.

Benca

Peterson

. Insomnia and depression. Sleep Med. 2008;9(Suppl 1):S3–S9.

27.

Serretti

Benedetti

Mandelli

Lorenzi

Pirovano

Colombo

Smeraldi

. Genetic dissection of psychopathological symptoms: insomnia in mood disorders and CLOCK gene polymorphism. Am J Med Genet B Neuropsychiatr Genet. 2003;121B(1):35–38.

28.

Bao

Meynen

Swaab

. The stress system in depression and neurodegeneration: focus on the human hypothalamus. Brain Res Rev. 2008;57(2):531–553.

29.

Taylor

Lichstein

Durrence

Reidel

Bush

. Epidemiology of insomnia, depression, and anxiety. Sleep. 2005;28(11):1457–1464.

30.

Ohayon

Roth

. Place of chronic insomnia in the course of depressive and anxiety disorders. J Psychiatr Res. 2003;37(1):9–15.

31.

Chellappa

Aeschbach

. Sleep and anxiety: From mechanisms to interventions. Sleep Med Rev. 2022;61:101583.

32.

Kalmbach

Anderson

Drake

. The impact of stress on sleep: pathogenic sleep reactivity as a vulnerability to insomnia and circadian disorders. J Sleep Res. 2018;27(6): e12710.

33.

Gosling

Batterham

Ritterband

, et al. Online insomnia treatment and the reduction of anxiety symptoms as a secondary outcome in a randomised controlled trial: the role of cognitive-behavioural factors. Aust N Z J Psychiatry. 2018;52(12):1183–1193.

34.

Cheatle

Foster

Pinkett

Lesneski

Dhingra

. Assessing and managing sleep disturbance in patients with chronic pain. Sleep Med Clin. 2016;11(4):531–541.

35.

Finan

Smith

. The comorbidity of insomnia, chronic pain, and depression: dopamine as a putative mechanism. Sleep Med Rev. 2013;17(3):173–183.

36.

Ostovar-Kermani

Arnaud

Almaguer

, et al. Painful sleep: insomnia in patients with chronic pain syndrome and its consequences. Folia Med. 2020;62(4):645–654.

37.

Wei

Blanken

Van Someren

EJW

. Insomnia really hurts: effect of a bad night’s sleep on pain increases with insomnia severity. Front Psychiatry. 2018;9:377.

38.

Wilson

Eriksson

D’Eon

Mikail

Emery

. Major depression and insomnia in chronic pain. Clin J Pain. 2002;18(2):77–83.

39.

Vitiello

Zhu

Von Korff

, et al. Long-term improvements in sleep, pain, depression, and fatigue in older adults with comorbid osteoarthritis pain and insomnia. Sleep. 2022; 45(2):zsab231.

40.

Lee

Chen

Guo

. Insomnia and the risk of atrial fibrillation: a population-based cohort study. Acta Cardiol Sin. 2017;33(2):165–172.

41.

Zhou

, et al. Healthy sleep patterns and risk of incident arrhythmias. J Am Coll Cardiol. 2021;78(12): 1197–1207.

Comorbidities and Risk Factors Associated With Insomnia in the Elderly Population

Abstract

Introduction/Objectives:

Methods:

Results:

Conclusions:

Keywords

Introduction

Materials and Methods

Study Design and Setting

Participants

Variables

Data Source and Access

Bias

Study Size

Statistical Methods

Results

Discussion

Conclusion

Footnotes

Acknowledgements

Author Contributions

Data Availability

Declaration of Conflicting Interests

Funding

Ethics

Informed Consent

ORCID iDs

References